Activated neutrophils contribute to the development of preterm delivery. Because of its ability to suppress inflammation, bikunin, a Kunitz-type protease inhibitor, is currently in clinical trials. To investigate the molecular mechanism of this inhibition, we analyzed the effect of bikunin on proinflammatory cytokine production and nuclear factor-kappaB (NF-κB) activation in mouse neutrophils stimulated by lipopolysaccharide (LPS), an inflammatory inducer. Here, we show that bikunin: (i) blocks LPS-induced secretion of pro-inflammatory cytokines, including TNF-α and IL-1β, in a dose-dependent manner; (ii) has an inhibitory effect on cytokine production at a concentration of 0.2 µM, reaching 65% inhibition at the highest doses of bikunin tested (5 µM); (iii) has the suppressive capacity of ERK1/2 and p38 signaling pathways; and (iv) inhibited sequentially the LPS-induced phosphorylation of IκB-α, degradation of IκB-α, and nuclear translocation of NF-κB. When the MAPK data are analyzed, a significant decrease in phosphorylation is not seen at 0.2 µM bikunin but is at 1.0 µM dosing. Bikunin can inhibit LPS-induced neutrophil activation and cytokine release, although it is unlikely that it works primarily through the inhibition of MAPK phosphorylation. These data suggest that such effects are important in vivo and play a major contributory role in abrogation of neutrophil-mediated inflammatory responses, such as preterm delivery.
INTRODUCTION
During bacterial infection, the functions of neutrophils are the killing of invading pathogens and resolution of associated inflammation. Neutrophils play a major role in causing tissue injury in acute inflammatory conditions. 1 The recruitment of neutrophils to inflammatory foci and injured tissues is a characteristic feature of host defense. 2 The importance of inflammation in the pathological responses to endotoxin (lipopolysaccharide, LPS) of foreign origin is well recognized. Inflammatory stimuli induce cytokines and respiratory burst, which mediate tissue responses in different phases of inflammation in a sequential and concerted manner. 3 Exposure of neutrophils to LPS leads to enhanced nuclear translocation of nuclear factor-kappaB (NF-κB) and production of pro-inflammatory cytokines, 4 such as tumor necrosis factor-α (TNF-α), macrophage inflammatory protein-2 (MIP-2), and interleukin-1β (IL-1β). [4] [5] [6] TNF-α mediates early-stage responses of inflammation by regulating the production of other cytokines, including IL-6.
Bikunin, a Kunitz-type protease inhibitor found in human amniotic fluid and urine, exhibits anti-inflammatory and anti-metastatic functions in animals 7 and humans. 8 The broad spectrum of the functions of bikunin suggests the existence of multiple molecular targets that mediate diverse responses to the compounds in cells. 9 Current understanding of the mechanism of action by bikunin comes mostly from studies on the suppression of several signaling cascades. 10 Upon exposure to bikunin, abrogation of calcium (Ca 2+ ) influx modulates the transcription of target genes through mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3 kinase (PI3K) dependent transcription. 10 Thus, suppression of signaling activation can account for prevention of inflammation by bikunin.
One of the risk factors for preterm birth is an intra-uterine infection or inflammation. 11 Chorio-amnionitis can cause preterm labor by provoking the release of inflammatory mediators in the decidua/fetal membrane area, leading to accumulation and activation of neutrophils and acceleration of the synthesis and release of pro-inflammatory cytokines (which start a vicious cycle), uterotonins such as prostaglandins (which cause uterine contractions) and metalloproteinases (that weaken fetal membranes and remodel cervical collagen). It is likely that treatment with a combination of antibiotics and prostaglandin synthase inhibitors and/or other anti-inflammatory drugs is the most appropriate therapeutic approach. Although bikunin suppresses the development of preterm delivery in animal experiments [12] [13] [14] [15] and in a clinical study, 16 the ability of bikunin to participate directly in LPS-induced neutrophil activation has not been examined. Bikunin has been shown to inhibit LPS-induced macrophage activation. 17, 18 The role of bikunin in modulating neutrophil responses initiated by exposure to LPS capable of producing neutrophil activation has not been investigated.
In the present study, we explored these issues and found that bikunin suppressed LPS-stimulated neutrophil activation. To our knowledge, this study is the first report of inhibition of LPS-induced pro-inflammatory cytokine production by bikunin. Our findings provide new insights into the mechanism of protection against inflammatory diseases, including preterm delivery, by bikunin.
MATERIALS AND METHODS

Reagents
All experiments were performed with LPS from Escherichia coli O111:B4 endotoxin (Sigma-Aldrich, Tokyo, Japan). For the generation of stock solutions, all reagents were dissolved in endotoxin-free water (Sigma-Aldrich). RPMI 1640 medium, DMEM and FCS were obtained from Invitrogen Japan K.K. (Tokyo, Japan). Bicinchoninic acid protein assay reagent was purchased from Pierce (Rockford, IL, USA). Activation-specific antibodies (Abs) for phospho-Thr202/Tyr204 extracellular receptor-activated kinase 1 (ERK1), phospho-Thr183/Tyr185 ERK2, phospho-Thr180/Tyr182 p38, phospho-Ser180/Ser181 IKK, phospho-Ser32 IκB-α, and total ERK1/2, p38, IκB-α, and NF-κB p50 were purchased from Cell Signaling Technologies (Beverly, MA, USA) and Santa Cruz Biotechnology (Santa Cruz, CA, USA). HRPlabeled anti-rabbit/goat Abs, and ECL reagents were purchased from Bio-Rad. Mouse anti-PARP-1 mAb (SA-250) was from BIOMOL Research Labs Inc. (Plymouth Meeting, PA, USA). Anti-β-actin was from Sigma-Aldrich. Bikunin purified from human urine was obtained from Mochida Pharmaceutical Co., Ltd (Tokyo, Japan). All other reagents were purchased from Sigma-Aldrich unless otherwise noted in the text. Custom-mixed Abs and columns for neutrophil isolation were purchased from Stem Cell Technologies (Vancouver, BC, Canada).
Isolation of mouse neutrophils
Bone marrow neutrophils in mice were isolated as described previously. 19 The cell suspension was incubated with primary Abs specific for cell surface markers F4/80, CD4, CD45R, CD5, and TER119. This custom cocktail is specific for T and B cells, RBCs, monocytes, and macrophages. Anti-biotin tetrameric Ab complexes were added with rotation. Colloidal magnetic dextran iron particles were added to the suspension and incubated with rotation. The entire cell suspension was then placed into a column, surrounded by a magnet. Neutrophils were obtained by negative selection methods. Neutrophil purity, as determined by Wright's stained cytospin preparations, was greater than 97%.
Human neutrophil preparation and culture
Blood was obtained from 10 consenting healthy volunteers and layered on a single-step Mono-Poly resolving medium (1.14 g/ml; MP Biomedicals Inc., Aurora, OH, USA). The cells were washed and resuspended in RPMI 1640 supplemented with 15% fetal bovine serum, 1% glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin (complete medium). These preparations contained greater than 90% neutrophils.
Stimulation protocol
In each experiment, bikunin was added to the cell cultures 1 h before stimulation with LPS. To analyze the inhibitory effect of bikunin on cytokine release, neutrophils (2 x 10 6 cells/well) were incubated with bikunin, and the cells were stimulated with LPS (1 mg/ml) at 37°C, with 5% CO 2 . At the indicated time point, supernatants, cell lysates, nuclear extracts were harvested and stored at -20°C.
MTT assay
To measure cell viability, the MTT assay was performed. Briefly, the cultured neutrophils (5 x 10 5 cells/well) were incubated with MTT (420 µg/ml), which is metabolized by living cells in 3 h. After solubilization of MTT crystals with HCl-isopropanol (150 µl/well), the optical density was determined at 570/690 nm.
Determination of cytokines
TNF-α and IL-1β proteins in supernatants were measured by a specific ELISA system (R & D Systems, Minneapolis, MN, USA), according to the manufacturer's instructions. 19 
Western blot analysis
Cells (1 x 10 6 ) were lysed in 750 µl of lysis buffer at 4°C for 15 min and scraped with a rubber policeman. The protein concentrations in the supernatants of cell extracts were measured by the protein assay. All samples were stored at -80°C until use. Centrifuged lysates (50 µg) were analyzed by SDS-polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride (PVDF) membrane by semi-dry transfer. Membranes were blocked for 1 h at room temperature in Tris-buffered saline containing 0.1% Tween 20 (TBST) and 2% BSA. Blots were probed with the primary Abs for phosphorylated and total kinases overnight at 4°C. PARP and β-actin served as controls for fractionation efficiency of nuclear and cytosolic proteins, respectively. The immunoblots were visualized by chemiluminescence with the ECL kit. Densitometry data for each protein are shown in graphic form, with baseline levels before LPS stimulation assigned a value of 100%.
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Statistical analysis
Data are expressed as mean ± SD of three independent triplicate experiments. Statistical analysis was performed by one-way analysis of variance (ANOVA) followed by the Student's t-test; P < 0.05 was considered statistically significant.
RESULTS
Bikunin inhibits LPS-induced secretion of pro-inflammatory cytokine by neutrophils
LPS has been shown to induce pro-inflammatory cytokines, including TNF-α and IL-1β, which have NF-κB binding sites in their promoters. 20 The transcriptional and post-transcriptional regulation of cytokine biosynthesis by LPS is well characterized in neutrophils 20 and macrophage cells. 21 To assess the role of bikunin in LPSinduced neutrophil activation, cells were pre-incubated with varying concentrations of bikunin for 1 h and then incubated with LPS for 90 min as described previously. 1 Very low amounts of TNF-α and IL-1β protein were detected by a specific ELISA for TNF-α and IL-1β in controls. Concentrations of these cytokines were increased in supernatants of neutrophils stimulated with 1 µg/ml LPS (Fig. 1A) . TNF-α production in neutrophils was inhibited by bikunin in a dose-dependent manner, reaching 65% inhibition at the highest doses of bikunin (Fig. 1B) . Bikunin alone did not affect its production. Bikunin did not affect MTT activity, given either alone or in combination (data not shown). These data demonstrate that bikunin does not cause marked damage to the cells at the concentrations tested. The results from all these assays together suggest that LPS-induced neutrophil activation, as indicated by secretion of proinflammatory cytokines, was inhibited by bikunin. The effect of bikunin on human neutrophils was also analyzed, as bikunin is suggested to be of clinical value. Treatment of human neutrophils with bikunin did not alter the basal level of cytokine synthesis (data not shown). Bikunin pretreatment also inhibited LPS-stimulated TNF-α production (Fig. 1A, compare lanes 9 and  10) and IL-1β production (Fig. 1B, compare lanes 9 and  10) in human neutrophils.
Bikunin inhibits LPS-induced phosphorylation of ERK1/2 and p38
LPS has been shown to induce activation of mitogenactivated protein kinases (MAPK), including ERK1/2 22 and p38 23 in neutrophils. All of these signal transductions are implicated in enhancing nuclear translocation of NF-κB. 24 Figure 2 shows the effects of bikunin on the phosphorylation of ERK1/2 ( Fig. 2A ) and p38 (Fig. 2B ) after exposure to 1 µg/ml LPS. Neutrophils were pretreated for 1 h with bikunin before LPS exposure. LPSinduced phosphorylation of ERK1/2 or p38 was inhibited by bikunin in a dose-dependent manner, with an IC 50 of 0.2-1.0 µM. A significant decrease in MAPK phosphorylation was not seen at 0.2 µM dosing but was at 1.0 µM dosing.
Bikunin inhibits nuclear translocation of NF-κB in LPS-stimulated neutrophils
LPS has been shown to induce nuclear translocation of NF-κB in neutrophils. 24 Figure 3 shows the effects of bikunin on the nuclear translocation of NF-κB after exposure to 1 µg/ml LPS for 40 min. Neutrophils were pretreated for 1 h with bikunin before LPS exposure. LPS-induced nuclear translocation of NF-κB was inhibited by bikunin in a dose-dependent manner, with an IC 50 of 1.0 µM. Again, a significant decrease in the nuclear translocation of NF-κB was seen at 5.0 µM dosing, reaching 40% inhibition at the highest doses of bikunin tested (5 µM).
Bikunin inhibits LPS-induced IκB degradation and phosphorylation
As described previously, 25 LPS treatment caused activation of NF-κB as demonstrated by measurement of IκB phosphorylation. NF-κB activation was determined by examining phosphorylation of IκB because degradation of IκB via its phosphorylation is necessary for nuclear translocation of NF-κB and subsequent activation of target gene expression. Therefore, the level of the IκB-α protein decreased as the phosphorylation level of the IκB-α protein increased. Pretreatment of bikunin blocked LPS-induced degradation (Fig. 4A ) and phosphorylation (Fig. 4B) of IκB-α, demonstrating that degradation and phosphorylation of IκB-α can be inhibited by bikunin. While bikunin significantly inhibits LPS-induced cytokine production at concentrations of 0.2 µM (Fig. 1) , it is ineffective at the same concentration on IκB activation and degradation. 
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DISCUSSION
We have studied the action of bikunin on production of proinflammatory cytokines in LPS-stimulated neutrophils. To our knowledge, the role of bikunin in affecting cytokine production in neutrophils has not previously been examined. We demonstrated that bikunin might block cytokine production by inhibiting activation of ERK1/2, p38, and NF-κB, although the effective dose of bikunin is different. When the MAPK data are analyzed, a significant decrease in phosphorylation is not seen at 0.2 µM dosing but is at 1-5 µM dosing. Bikunin has a significant effect on cytokine production at a concentration of 0.2 µM. The MAPK pathways may play a role at higher dosing of the drug but this does not account for its effects at the 0.2 µM dose. Our observation that bikunin decreased MAPK activation and NF-κB nuclear translocation only partially indicates that there are other mechanisms leading to suppression of cytokine production.
Increased activation of the MAPKs ERK1/2 and p38, phosphoinositide 3-kinases (PI3-K), and NF-κB are involved in neutrophil activation. 26 NF-κB can be activated by several pathways including Akt and IRAK. 27 PI3-K and the downstream serine/threonine kinase Akt have a central role in modulating neutrophil activation, chemotaxis, and apoptosis. 28 PI3-K and Akt have been shown to participate in signaling pathways that lead to NF-κB activation and increased NF-κB-dependent transcription. 29 Our data showed that the LPS-stimulated JNK activation was not inhibited by bikunin (unpublished data; Kobayashi et al. 2007 ). Incubation of neutrophils with LPS resulted in phosphorylation of Akt. 28 Addition of the PI3-K inhibitor LY294002 to the neutrophil cultures prevented LPS-associated Akt phosphorylation 28 but bikunin did not affect the LPS-induced activation of Akt (unpublished data; Kobayashi et al. 2007 ). These data allow us to speculate that bikunin specifically inhibits ERK1/2 and p38 pathways.
The inhibition by bikunin is not specific for neutrophils. The effect of bikunin on LPS-induced activation of signal transduction and pro-inflammatory cytokine expression has been studied in macrophages. 17, 18 Our observation that 
A B
Densitometric Analysis Densitometric Analysis bikunin down-regulated the MAPK signaling and cytokine production also agrees with results from other studies using cancer cells. 30 Data on the effects of bikunin on signal transduction and cytokine production in neutrophils are lacking. It is unclear in neutrophils, however, if bikunin works primarily through the inhibition of MAPK phosphorylation. There still remain several possibilities that bikunin inhibits expression of pro-inflammatory cytokines in LPS-stimulated neutrophils via other mechanisms. It should be noted that in our experiments on cytokine secretion, the neutrophil preparation was greater than 95% pure but did contain a small percentage of monocytes that may have taken part in cytokine secretion.
Kinases shown to be activated by LPS include not only MAPKs (ERK1/2 and P38) but also Syk, Akt, and the IKK complex, 1 which results in activation of NF-κB. We assume that inhibition of LPS-induced signaling pathways other than MAPKs is implicated in the suppressive effects of bikunin. It is generally recognized that Ca 2+ influx into a certain cells is essential for MAPK activation. 31, 32 The effect of bikunin on changes in cytosolic free Ca 2+ is mainly derived from Ca 2+ influx studies. 33 However, since LPS alone does not cause an increase in intracellular Ca 2+ influx, it is unlikely that bikunin works predominantly through the inhibition of Ca 2+ influx-induced MAPK activation in neutrophils primed with LPS.
The Toll-like receptor 4 (TLR4) is an essential receptor for LPS signaling and is the main protein involved in recognizing Gram-negative bacteria and LPS. 34 We have examined the expression of TLR4 in bikunin-treated neutrophils. We tested whether bikunin reduces TLR4 expression or LPS-binding in this study. Flow cytometry analysis demonstrated that neutrophils express lower levels of TLR4. Treatment of human neutrophils with 10 ng/ml LPS alone did not affect the expression of TLR4. It has been established that the combination of 10 ng/ml LPS and IFN-γ significantly enhanced the surface expression of TLR4 compared with IFN-γ alone or LPS alone. 35 Therefore, we could not confirm the observation that bikunin suppressed LPS-induced up-regulation of TLR4 on human neutrophils.
Because TNF-α is the main mediator for a number of inflammatory toxic responses to chemicals, it represents a promising target for the prevention of inflammatory toxicity. These findings provide evidence that regulation of TNF-α production serves as an effective target of anti-inflammation, including preterm delivery. 6 The role of neutrophil-dependent cytokines in preterm delivery has been demonstrated. 31 Overall, the ability of bikunin to down-regulate pro-inflammatory cytokines provides novel targets for therapy of preterm delivery. 36 For the dose-escalation portion of the preliminary study, patients received 25, 75, or 150 mg bikunin. After an i.v. injection (150 mg bikunin), maximum plasma (peak) drug concentration (about 2 µM) after single-dose administration (C max ) was achieved 5-15 min postdosing with an arithmetic mean half-life associated with terminal slope of a semilogarithmic concentration-time curve (t 1/2λz ) of 0.7 h. Plasma concentrations over 0.2 µM ranged from 2-4 h for a single administration of 150 mg bikunin (data from Mochida Pharmaceutical Company, Tokyo, Japan).
CONCLUSIONS
The MAPK pathways may play a role at higher dosing of bikunin but do not account for its effects at a lower dose. Although the mechanism of anti-inflammation by bikunin is still unclear, this study is the first report of inhibition of cytokine secretion by bikunin in the LPSstimulated neutrophils. Our results suggest a mechanism of anti-inflammation by bikunin through control of cytokine induction during inflammation-induced preterm delivery. Analyses of the molecular mechanism by which bikunin suppresses activation of target proteins will provide new insights into the mechanism of antiinflammatory action, regulation of cytokine production, and control of NF-κB function.
